TABLE 2.
Concomitant antithrombotic therapy.
| Agents | Patients, n (%) a |
|---|---|
| Platelet aggregation inhibitors | 112 (51.9) |
| Acetylsalicylic acid | 105 (48.6) |
| Clopidogrel | 7 (3.2) |
| Ticagrelor | 2 (0.9) |
| Dipyridamole | 1 (0.5) |
| Prasugrel | 1 (0.5) |
| Direct factor Xa inhibitors | 79 (36.6) |
| Apixaban | 56 (25.9) |
| Rivaroxaban | 22 (10.2) |
| Edoxaban | 4 (1.9) |
| Heparins | 40 (18.5) |
| Enoxaparin | 29 (13.4) |
| Heparin | 15 (6.9) |
| Dalteparin | 1 (0.5) |
| Sulodexide | 1 (0.5) |
| Salicylic acid and derivatives | 12 (5.6) |
| Acetylsalicylic acid b | 12 (5.6) |
| Thrombolytics | 5 (2.3) |
| Alteplase c | 5 (2.3) |
a
Patients may have received more than one type/subtype of concomitant antithrombotic therapy.
b
Patients were taking salicylic acid and derivatives for indications besides platelet aggregation inhibition including pain management, fever, and other uses.
c
Among the five patients who received thrombolytics, three appeared to have been for prevention or treatment of central venous catheter occlusions and two were for unknown reasons.